BioCentury | Apr 4, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: March 2018

New Therapeutic Targets and Biomarkers: March 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Apr 3, 2018
Translation in Brief

Strong-arming drug delivery

In a Nature Communications study, a Harvard team developed extracellular vesicles that can deliver a variety of macromolecular cargo inside target cells or tissues, paving the way for therapeutics against traditionally intractable intracellular targets. Previously,...
BioCentury | Mar 28, 2018
Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles ARRDC1-containing microvesicles could be used to deliver therapeutic macromolecules. The method involves engineering HEK cells to express ARRDC1 for enhanced formation of extracellular microvesicles that incorporate three types of cargo co-expressed in the...
BioCentury | Sep 15, 2016
Distillery Therapeutics

Therapeutics: MLX interacting protein (MLXIP); thioredoxin interacting protein (TXNIP); arrestin domain containing 4 (ARRDC4)

Endocrine/metabolic disease INDICATION: Obesity Cell culture and mouse studies suggest inhibiting the MLXIP / TXNIP / ARRDC4 pathway could help treat obesity. In cultured human skeletal myotubes, siRNA targeting MLXIP or a MLXIP inhibitor tool...
BioCentury | Oct 27, 2011
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...greater ARRDC3 expression than normal-weight males. The increased expression correlated with higher body mass index. Arrdc3-deficient...
...insulin resistance and increased energy expenditure compared with wild-type controls. Next steps include directly targeting ARRDC3...
Items per page:
1 - 5 of 5